Model Number G43826 |
Device Problems
Off-Label Use (1494); Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Aneurysm (1708); Thrombosis/Thrombus (4440)
|
Event Date 01/18/2021 |
Event Type
Injury
|
Manufacturer Narrative
|
Pma/510(k) #: p050017/s002 and s003.Investigation is still pending, a follow up mdr will be submitted to include the investigation conclusions.
|
|
Event Description
|
This patient has had numerous cts and a total of 4 secondary interventions throughout participation in this study.To simplify these cts (as related to this event), please see the table uploaded as an attached file the table provides the date of the imaging, the number of days post-procedure, the maximum aneurysm diameter and presence of an endoleak (as reported by the clinical study site or the core laboratory).Also included is the secondary interventions, the indication for them and the treatments.A ct dated (b)(6) 2021 revealed an enlarging aneurysm.The clinical study site was unable to identify an endoleak and reported the maximum aneurysm diameter was 73mm.The core laboratory evaluation of the ct identified a definite endoleak but the source could not be determined and was listed as an unknown endoleak.A second ct scan dated (b)(6) 2021 was completed.The site again could not identify an endoleak, but continued aneurysm enlargement, now 77mm, led the site to schedule a secondary intervention.Core laboratory evaluation of the ct again revealed an unknown type endoleak.On (b)(6) 2021 (1705 days post-procedure) the patient underwent a secondary intervention to place a proximal aortic cuff extension as well as a left iliac stent graft extension with kissing stents in the left external and internal iliac arteries.Per op-note ¿presumed type 1a and 1b endoleak¿ treated with placement of (36 mm medtronic) proximal aortic cuff extension, distal left iliac stent graft extension (with a 9 x 59 vbx gore stent into the left internal iliac and a 9mm x 79 mm vbx gore stent in the left external iliac artery).The secondary intervention was considered successful.Post procedure angiography revealed the devices were patent with no endoleak or device integrity issues noted.No aortogram was submitted for core laboratory evaluation.
|
|
Manufacturer Narrative
|
Pma/510(k) #: p050017/s002 and s003.This file is related to complaint file (b)(4) (emdr 3001845648-2021-00493).Device evaluation: the ziv6-35-125-7-40 device of lot number c1177251 involved in this complaint was not returned for evaluation.With the information provided, a document-based investigation was conducted.This file is related to study (b)(6); "patient (b)(6) ¿ unknown endoleak 1652 days post-procedure (ct dated 1/18/2021) and secondary intervention".Document review: prior to distribution ziv6-35-125-7-40 devices are subjected to a visual inspection and functional checks to ensure device integrity.These inspections and functional checks are outlined in internal procedures in place at cirl.A review of the manufacturing records for ziv6-35-125-7-40 of lot number c1177251 did not reveal any discrepancies that could have contributed to this complaint issue.The instructions for use (ifu0043) states the following: ¿the zilver vascular stent is intended for use as an adjunct to percutaneous transluminal angioplasty (pta) in the treatment of symptomatic vascular disease of the iliac arteries¿.There is evidence to suggest the user did not follow the ifu.Root cause review: a definitive root cause of off- label use was identified from the available information.As per medical advisor "i¿m not sure what is meant by distal atrium as i cannot imagine they have used the zilver flex in the heart however i do not have access to the entire procedural description where distal atrium is mentioned.Either way i do not think it refers to the iliac arteries so would be off-label." summary: the complaint is confirmed based on customer testimony.According to the initial reporter, the secondary intervention was considered successful.The patient remains in the study.Complaints of this nature will continue to be monitored for potential emerging trends.
|
|
Event Description
|
Off label use confirmed on 11-may-2022 investigation was subsequently completed on 27-may-2022.
|
|
Manufacturer Narrative
|
Pma/510(k) #p050017/s002 and s003.Supplemental correction report is being submitted due to the file being re-opened per pms review to update origin of complaint and update to annex c code from c13 to c23 on 13-dec-2023.This file is related to complaint file (b)(4).Device evaluation: the ziv6-35-125-7-40 device of lot number c1177251 involved in this complaint was not returned for evaluation.With the information provided, a document-based investigation was conducted.This file is related to study (b)(6); "patient (b)(6) ¿ unknown endoleak 1652 days post-procedure (ct dated 1/18/2021) and secondary intervention".Lab evaluation: n/a.Document review: prior to distribution ziv6-35-125-7-40 devices are subjected to a visual inspection and functional checks to ensure device integrity.These inspections and functional checks are outlined in internal procedures in place at cirl.A review of the manufacturing records for ziv6-35-125-7-40 of lot number c1177251 did not reveal any discrepancies that could have contributed to this complaint issue.The instructions for use (ifu0043) states the following: ¿the zilver vascular stent is intended for use as an adjunct to percutaneous transluminal angioplasty (pta) in the treatment of symptomatic vascular disease of the iliac arteries¿.There is evidence to suggest the user did not follow the ifu.Image review ¿ n/a.Root cause review: a definitive root cause of off- label use was identified from the available information.As per medical advisor "i¿m not sure what is meant by distal atrium as i cannot imagine they have used the zilver flex in the heart however i do not have access to the entire procedural description where distal atrium is mentioned.Either way i do not think it refers to the iliac arteries so would be off-label.Summary: the complaint is confirmed based on customer testimony.According to the initial reporter, the secondary intervention was considered successful.The patient remains in the study.Complaints of this nature will continue to be monitored for potential emerging trends.
|
|
Event Description
|
Supplemental correction report is being submitted due to the file being re-opened per pms review to update origin of complaint and update to annex c code from c13 to c23 on 13-dec-2023.
|
|
Search Alerts/Recalls
|